Cargando…

Benefits of different postoperative treatments in patients undergoing knee arthroscopic debridement

PURPOSE: To assess the effectiveness of viscosupplementation or platelet-rich plasma (PRP), compared to standard care, for pain relief after knee arthroscopic debridement in patients with meniscal pathology and osteoarthritis (OA), under normal clinical practice conditions. PATIENTS AND METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Trueba Vasavilbaso, Cesáreo, Rosas Bello, Carlos David, Medina López, Erla, Coronel Granado, Maria Pilar, Navarrete Álvarez, José Mario, Trueba Davalillo, Cesáreo Angel, Gil Orbezo, Félix Isaac
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626376/
https://www.ncbi.nlm.nih.gov/pubmed/29026341
http://dx.doi.org/10.2147/OARRR.S138353
_version_ 1783268533908537344
author Trueba Vasavilbaso, Cesáreo
Rosas Bello, Carlos David
Medina López, Erla
Coronel Granado, Maria Pilar
Navarrete Álvarez, José Mario
Trueba Davalillo, Cesáreo Angel
Gil Orbezo, Félix Isaac
author_facet Trueba Vasavilbaso, Cesáreo
Rosas Bello, Carlos David
Medina López, Erla
Coronel Granado, Maria Pilar
Navarrete Álvarez, José Mario
Trueba Davalillo, Cesáreo Angel
Gil Orbezo, Félix Isaac
author_sort Trueba Vasavilbaso, Cesáreo
collection PubMed
description PURPOSE: To assess the effectiveness of viscosupplementation or platelet-rich plasma (PRP), compared to standard care, for pain relief after knee arthroscopic debridement in patients with meniscal pathology and osteoarthritis (OA), under normal clinical practice conditions. PATIENTS AND METHODS: We conducted a prospective, randomized, evaluator-blind, pilot study. After arthroscopy, patients were randomized to receive 1) five injections of HA1 (Suprahyal(®)/Adant(®)); 2) four injections of HA2 (Orthovisc(®)); 3) three injections of HA3 (Synvisc(®)); 4) a single injection of PRP (GPS™ II); or 5) standard care (control). Patients were followed up for 18 months. Clinical outcomes were evaluated using the Western Ontario and McMaster Universities Arthritis Index (WOMAC) at 3, 6, 12, and 18 months. Minimally Clinical Important Improvement (MCII), as relative improvement ≥20 for pain and function, was also calculated. RESULTS: Fifty patients were included. At early follow-up (3 months), total WOMAC scores improved in all groups compared to baseline with reductions of 44.79% (HA1), 24.02% (HA2), 40.38% (HA3), 39.77% (PRP), and 27.64% (control) (p=0.002 HA1 compared to HA2). At 18 months, the higher improvement in total WOMAC was in HA1 with a 65.20% reduction, followed by PRP (55.01%), HA3 (49.57%), and HA2 (29.82%), whereas the control group had a 14.55% increase over baseline (p=0.001 control compared to HA1 and HA3). The percentage of patients achieving the MCII for both pain and function at 18 months was 100% (HA1), 80% (HA3), 60% (HA2), and 60% (PRP), whereas, in the control group, all patients returned to pre-arthroscopy levels. There were no adverse events attributable to surgery or to intraarticular administration. CONCLUSION: Viscosupplementation following arthroscopy is more effective than PRP in adequately selected patients with meniscal lesions occurring concomitantly with OA. Further controlled studies with a larger sample size and/or alternative regimens would be of interest for the scientific community.
format Online
Article
Text
id pubmed-5626376
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56263762017-10-12 Benefits of different postoperative treatments in patients undergoing knee arthroscopic debridement Trueba Vasavilbaso, Cesáreo Rosas Bello, Carlos David Medina López, Erla Coronel Granado, Maria Pilar Navarrete Álvarez, José Mario Trueba Davalillo, Cesáreo Angel Gil Orbezo, Félix Isaac Open Access Rheumatol Original Research PURPOSE: To assess the effectiveness of viscosupplementation or platelet-rich plasma (PRP), compared to standard care, for pain relief after knee arthroscopic debridement in patients with meniscal pathology and osteoarthritis (OA), under normal clinical practice conditions. PATIENTS AND METHODS: We conducted a prospective, randomized, evaluator-blind, pilot study. After arthroscopy, patients were randomized to receive 1) five injections of HA1 (Suprahyal(®)/Adant(®)); 2) four injections of HA2 (Orthovisc(®)); 3) three injections of HA3 (Synvisc(®)); 4) a single injection of PRP (GPS™ II); or 5) standard care (control). Patients were followed up for 18 months. Clinical outcomes were evaluated using the Western Ontario and McMaster Universities Arthritis Index (WOMAC) at 3, 6, 12, and 18 months. Minimally Clinical Important Improvement (MCII), as relative improvement ≥20 for pain and function, was also calculated. RESULTS: Fifty patients were included. At early follow-up (3 months), total WOMAC scores improved in all groups compared to baseline with reductions of 44.79% (HA1), 24.02% (HA2), 40.38% (HA3), 39.77% (PRP), and 27.64% (control) (p=0.002 HA1 compared to HA2). At 18 months, the higher improvement in total WOMAC was in HA1 with a 65.20% reduction, followed by PRP (55.01%), HA3 (49.57%), and HA2 (29.82%), whereas the control group had a 14.55% increase over baseline (p=0.001 control compared to HA1 and HA3). The percentage of patients achieving the MCII for both pain and function at 18 months was 100% (HA1), 80% (HA3), 60% (HA2), and 60% (PRP), whereas, in the control group, all patients returned to pre-arthroscopy levels. There were no adverse events attributable to surgery or to intraarticular administration. CONCLUSION: Viscosupplementation following arthroscopy is more effective than PRP in adequately selected patients with meniscal lesions occurring concomitantly with OA. Further controlled studies with a larger sample size and/or alternative regimens would be of interest for the scientific community. Dove Medical Press 2017-09-25 /pmc/articles/PMC5626376/ /pubmed/29026341 http://dx.doi.org/10.2147/OARRR.S138353 Text en © 2017 Trueba Vasavilbaso et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Trueba Vasavilbaso, Cesáreo
Rosas Bello, Carlos David
Medina López, Erla
Coronel Granado, Maria Pilar
Navarrete Álvarez, José Mario
Trueba Davalillo, Cesáreo Angel
Gil Orbezo, Félix Isaac
Benefits of different postoperative treatments in patients undergoing knee arthroscopic debridement
title Benefits of different postoperative treatments in patients undergoing knee arthroscopic debridement
title_full Benefits of different postoperative treatments in patients undergoing knee arthroscopic debridement
title_fullStr Benefits of different postoperative treatments in patients undergoing knee arthroscopic debridement
title_full_unstemmed Benefits of different postoperative treatments in patients undergoing knee arthroscopic debridement
title_short Benefits of different postoperative treatments in patients undergoing knee arthroscopic debridement
title_sort benefits of different postoperative treatments in patients undergoing knee arthroscopic debridement
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626376/
https://www.ncbi.nlm.nih.gov/pubmed/29026341
http://dx.doi.org/10.2147/OARRR.S138353
work_keys_str_mv AT truebavasavilbasocesareo benefitsofdifferentpostoperativetreatmentsinpatientsundergoingkneearthroscopicdebridement
AT rosasbellocarlosdavid benefitsofdifferentpostoperativetreatmentsinpatientsundergoingkneearthroscopicdebridement
AT medinalopezerla benefitsofdifferentpostoperativetreatmentsinpatientsundergoingkneearthroscopicdebridement
AT coronelgranadomariapilar benefitsofdifferentpostoperativetreatmentsinpatientsundergoingkneearthroscopicdebridement
AT navarretealvarezjosemario benefitsofdifferentpostoperativetreatmentsinpatientsundergoingkneearthroscopicdebridement
AT truebadavalillocesareoangel benefitsofdifferentpostoperativetreatmentsinpatientsundergoingkneearthroscopicdebridement
AT gilorbezofelixisaac benefitsofdifferentpostoperativetreatmentsinpatientsundergoingkneearthroscopicdebridement